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ABSTRACT
Introduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no 
specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical 
outcomes.
Areas covered: This systematic review summarizes the available evidence for all biomarkers proposed 
to have a role in the diagnosis or prognosis of DILI. Following a comprehensive search, we included all 
types of studies in humans. We included DILI cases based on any threshold criteria but excluded 
intrinsic DILI, commonly caused by paracetamol overdose. We classified studies into diagnostic and 
prognostic categories and assessed their methodological quality. After reviewing the literature, 14 
studies were eligible.
Expert Opinion: Diagnostic studies were heterogeneous with regard to the study population and 
outcomes measured. Prognostic models were developed by integrating novel biomarkers, risk scores, 
and traditional biomarkers, which increased their prognostic ability to predict death or transplantation 
by 6 months. This systematic review highlights the case of need for non-genetic biomarkers that 
distinguish DILI from acute liver injury related to alternative etiology. Biomarkers with the potential 
to identify serious adverse outcomes from acute DILI should be validated in independent prospective 
cohorts with a substantial number of cases.
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Idiosyncratic drug-induced liver injury (DILI) is an unpredict-
able and serious adverse event with an annual incidence 
estimated to be 19.1 and 23.8 per 100,000 in Iceland and 
mainland China, respectively [1,2]. Nonetheless, the inci-
dence of DILI secondary to commonly used medications is 
significantly higher, reaching 43 per 100,000 users of amox-
icillin-clavulanate [1]. Liver biochemistry remains the main-
stay of DILI detection followed by causality assessment to 
identify a temporal relationship between the suspected 
drug and the liver injury, taking multiple factors into 
account. They include the time and course of injury in 
relation to the medication, concomitant drugs, patient’s 
risk factors, exclusion of other etiologies, drug’s hepatotoxi-
city profile, and response to re-administration when applic-
able. Therefore, an acute elevation of serum liver enzymes 
(alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP), and gamma-glutamyl
transferase (GGT)) following drug administration without 
other clear clinical reasons is suggestive of DILI [3]. 
Elevated total bilirubin, specifically conjugated bilirubin, in 
addition to liver enzymes, can also indicate severe liver 
injury. However, these markers lack specificity and do not 
distinguish DILI from other liver etiologies, which can cause 
a similar elevation in liver enzymes. Moreover, an acute rise 
in ALT and AST, which may be interpreted as hepatocellular 
injury, can be secondary to muscle or cardiac injury. 
Additionally, asymptomatic elevation in transaminases asso-
ciated with medications such as cholestyramine and heparin 
do not reflect clinically relevant liver injury [4,5], while vari-
able proportion of ALT elevations temporally related to drug 
exposure resolve spontaneously despite continued medica-
tion [6]. Yet, there is no universal gold standard for the 
diagnosis of DILI [7]. When multiple medications are taken 
simultaneously, it is frequently difficult to single out the 
agent that has caused DILI [8]. Therefore, diagnosis of
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idiosyncratic DILI remains challenging in new drug develop-
ment and clinical practice, and there is an urgent need for 
sensitive and specific DILI biomarkers.
Definition of DILI based on liver enzymes elevation lacked 
standardization until 2011, when the international consensus 
and the European Association for the Study of the Liver pro-
posed threshold criteria for the definition of DILI, which have 
been implemented since in clinical practice [3,9]. The pattern 
of DILI is based on the earliest identified liver chemistry eleva-
tions above the upper limit of normality (ULN) that fit DILI 
criteria and is defined using R ratio, where R = (ALT/ 
ULN)÷(ALP/ULN). There are three patterns of DILI: hepatocel-
lular (R ≥ 5), mixed (R > 2 and < 5), and cholestatic (R ≤ 2).
The degree of elevation of liver enzymes does not accu-
rately reflect the severity of the liver injury or predict clinical 
outcome. However, elevated liver enzymes and total bilirubin 
indicate a worse prognosis, which was observed by Hyman 
Zimmerman several decades ago and became the basis of Hy’s 
law, which is defined by drug-induced liver injury with ALT > 3 
times ULN and total bilirubin >2 ULN after excluding other 
causes [10]. Furthermore, multiple registries demonstrated 
mortality/liver transplant rates exceed 10% in DILI patients 
with a hepatocellular injury with jaundice [11,12]. This usually 
leads to permanent discontinuation of the investigated drug 
in clinical trials. Since the risk is 10%, most patients who meet 
Hy’s law criteria will spontaneously recover without liver trans-
plantation. Therefore, although this makes Hy’s law a useful 
tool for initial risk assessment and a predictor of a drug’s 
potential to cause severe hepatotoxicity, it lacks the specificity 
required for a decision-making algorithm [10].
Due to the clinical need for sensitive and specific biomar-
kers for DILI, multiple new biomarkers have been studied in 
the last few decades. Most studies were mainly in the context 
of paracetamol-induced DILI, which may differ from
idiosyncratic DILI due to different pathogenesis of liver injury 
and early clinical presentation. The development of biomar-
kers has received regulatory support from the Food and Drug 
Adminstration (FDA) [13,14]. Despite the efforts put by the 
Predictive Safety Testing Consortium in the USA and the for-
mer Safer and Faster Evidence-based Translation Biomarker 
Consortium in Europe in the last few decades, novel biomar-
kers have failed to reach full qualification and application in 
clinical practice [15,16]. Due to the increasing interest and 
importance in clinical practice, a systematic review is war-
ranted to summarize the available evidence of biomarkers 
for idiosyncratic DILI in humans.
2. Methods
This systematic review was structured in accordance with the 
PRISMA checklist and Cochrane handbook for systematic 
reviews of diagnostic test accuracy [17]. It was registered in 
PROSPERO (registration number: CRD42020168708). We 
included all types of studies published in English regardless 
of publication status or whether data were collected prospec-
tively or retrospectively. We included studies that provided 
information comparing one or more diagnostic or prognostic 
biomarkers against traditional index tests in patients with 
idiosyncratic DILI.
2.1. Study design and search strategy
We searched MEDLINE via OvidSP (January 1946 to 10/03/ 
2021) and Embase via OvidSP (January 1947 to 10/03/2021) 
and restricted our search results to English language and adult 
population. We designed structured search strategies using 
controlled search terms appropriate for each database as 
well as free-text search terms. The search strategy for 
MEDLINE is shown in Supplementary Material 1. We also 
searched Scopus, Cochrane Controlled Register of Trials, 
OpenGrey databases, and clinical trial registers for additional 
trials (EU Clinical trials register (www.clinicaltrialsregister.eu) 
and Clinicaltrials.gov (www.clinicaltrials.gov)) within the same 
temporal framework as above mentioned. We screened the 
reference lists of all relevant papers to retrieve additional 
studies and searched for similar articles related to the final 
included studies. We contacted relevant authors for further 
details about the studies when required. We did not perform 
hand-searching, as there is little published evidence of the 
benefits of hand-searching for reports of diagnostic test accu-
racy studies [18].
2.2. Inclusion and exclusion criteria
The inclusion criteria were adult population with suspected 
DILI or hepatotoxicity with raised liver enzymes (ALT, AST, and 
ALP) based on any threshold criteria. Exclusion criteria were 
cases with intrinsic (direct) DILI, commonly caused by para-
cetamol overdose. The index tests studied were all non- 
genetic biological markers in humans, and we excluded purely 
mechanistic studies that were done exclusively in vitro. There
Article Highlights
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is no reference standard available for DILI, and clinical diagnosis 
is usually based on biochemical alteration and causality assess-
ments. European and American DILI registries (Pro-Euro DILI 
Network and Drug Induced Liver Injury Network (DILIN)) have 
an established adjudication process with a panel of experts in 
the field to make the final decision on the diagnosis [19].
2.3. Outcome definitions
The main outcomes in the diagnostic category were per-
formance characteristics of non-genetic biomarkers, alone 
or in combination, to distinguish DILI from other etiologies 
that form competing diagnoses. In the prognostic cate-
gory, the primary outcome was accuracy in predicting 
clinical endpoints 6 months after DILI onset (recovery, 
persistent DILI, acute liver failure, liver transplant, and 
death).
2.4. Study selection
Three review authors (EA, CF, and IAA) independently 
identified relevant studies. We retrieved studies from refer-
ences that at least one of the review authors judged as 
relevant. Two review authors independently assessed the 
full-text articles. We resolved any differences in study 
selection by discussion. For data extraction, only data 
from studies that meet the inclusion criteria were used. 
We included all types of studies published in English 
regardless of publication status or whether data were col-
lected prospectively or retrospectively. We included studies 
that provided information comparing one or more diag-
nostic or prognostic biomarkers against traditional index 
tests in patients with idiosyncratic DILI. We considered 
data from abstracts if they meet the inclusion criteria and 
contained sufficient relevant data.
2.5. Data extraction and quality assessment
Two review authors (EA and IAA) independently extracted 
the following data from each included study: first 
author, year of publication, study design (prospective or 
retrospective; cross-sectional studies or case-control studies 
that reported results of diagnostic accuracy of biomarkers in 
people with suspected DILI); inclusion and exclusion criteria 
for individual studies; the total number of participants; the 
number of males and females; mean age of the participants; 
severity of DILI; participants’ risk factors of liver disease; 
tests carried out before testing biomarkers; biomarkers 
tested (index tests); reference standard; and true positive, 
false positive, true negative, and false-negative data with 
receiver operator characteristic curve. When necessary, we 
sought further information from the authors of the studies. 
Disagreements between the review authors were resolved 
by discussion. We used the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool to evaluate 
the quality of diagnostic studies and Quality in the 
Prognostic Studies (QUIPS) tool for prognostic studies 
[20,21]. We evaluated the two segments of QUADAS-2 eva-
luation separately, i.e. the risk of bias and applicability. We 
adjusted signaling questions according to our review. Each 
of the included studies was independently assessed by two 
review authors (EA and IAA).
2.6. Statistical analysis and data synthesis
We summarized the findings from the included studies in 
a narrative synthesis and classified them based on the type 
of DILI biomarkers (diagnostic and prognostic), following FDA 
definitions [22]. We aimed to perform a quantitative analysis 
to evaluate the diagnostic and prognostic accuracy of the 
biomarkers, but it was not adequate due to heterogeneity of 
the study population and outcomes measured. We summar-
ized the performance characteristics of all the diagnostic and 
prognostic biomarkers and calculated unreported sensitivity, 
specificity, and the area under the receiver operating charac-




Out of 5,809 records (following removal of duplicated), we 
excluded 5,596 irrelevant papers. We retrieved and 
reviewed a total of 213 full-text reports to assess their 
eligibility for inclusion in the review as illustrated in the 
flow diagram. The identified studies that investigated 
urine-based biomarkers were done in animal models and 
in the context of intrinsic DILI; therefore, they were 
excluded. We excluded 34 studies in humans that did not 
meet our eligibility criteria. The most common reasons for 
exclusion were intrinsic DILI secondary to paracetamol 
overdose and conference abstracts from included papers 
with insufficient data. We also identified seven registered 
trials on www.clinicaltrials.gov with unpublished results 
and two trials that are currently ongoing (NCT04269486 
and NCT02353455). Figure 1 presents a schematic overview 
of the study selection process.
We finally included 14 studies in the review and classi-
fied them into two main categories: diagnostic and prog-
nostic. All studies investigated blood-based biomarkers; we 
provided a summary of all included studies in Table 1.
4. Findings
We have sub-grouped the results into diagnostic and prog-
nostic domains. Out of 14 included full texts, we classified 
eight studies as diagnostic, four studies as prognostic, and 
two studies as both diagnostic and prognostic.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 1329
4.1. Diagnostic studies
4.1.1. Study design
Ten studies investigated the diagnostic ability of biomarkers in 
DILI. All studies were case control in design, with healthy controls 
being the main comparator to DILI. Five studies compared DILI 
with patients receiving drugs or herbal medicine known to cause 
DILI without developing liver injury [23–27]. Three studies 
included patients with liver injury from other etiologies. Dragoi 
et al. had patients with acute liver injury unrelated to drug [23], 
whereas Soga et al. had patients with chronic liver diseases and 
Huang et al. included patients with autoimmune hepatitis and 
hepatitis-B virus infection during an acute flare [28,29].
The DILI population varied across the diagnostic studies. 
Five studies investigated biomarkers for liver injury secondary 
to specific drugs; one small study investigated dicolofenac-
induced liver injury [23], two prospective studies focused on 
HIV/tuberculosis medications [24,26] and two Chinese studies 
investigated liver injury secondary to the herbal medicine, 
Polygonum multiflorum Thunb (PM) [25,29]. In contrast, three 
studies used samples from DILI patients recruited as part of 
the DILIN prospective multicenter study in the USA. Bell et al. 
and Steuerwald et al. included samples from the same DILIN 
cohort [30,31], whereas Church et al. combined DILIN samples 
with two other cohorts from SAFE-T network and had the 
largest number of DILI samples overall [27].
The threshold of liver enzymes used to define acute liver 
injury varied across studies as per Table 1. One study, Ma 
et al., defined DILI as ALT > 40 U/L and total bilirubin (TBL) 
>20 µmol/L [32], whereas Thulin et al. defined it as ALT > 3 
times ULN similar to SAFE-T cohorts [24]. Rupprechter et al. 
described DILI as ALT > 3 times ULN with symptoms or > 5
Figure 1. Study selection flow diagram.
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times ULN without symptoms; however, due to a low number 
of DILI cases (2 cases), the comparison was performed with 
a lower threshold of ALT elevation (50 U/L, ULN) [26]. Zhang 
et al. defined patients as susceptible to DILI following an 
elevation of ALT > 2 ULN. DILIN cohort had the highest 
threshold of ALT (>5 times ULN) [25].
4.1.2. Performance characteristics of diagnostic 
biomarkers
Studies were heterogeneous, assessed different biomarkers in 
different populations, thus precluded the combination of the 
results into a meta-analysis. Alternatively, we provided 
a narrative summary of their main findings and grouped 
them by the type of diagnostic biomarkers explored. The 
area under the receiver operating curve (AUROC) was com-
monly used to assess the performance characteristics of bio-
markers. We summarized the diagnostic accuracies of 
biomarkers studied in Table 2. We have divided the studies 
according to the type of index tests studied into four sub-
groups: proteomics, metabolomics, immune-analytes, and can-
didate biomarkers.
4.1.2.1. Proteomics. Dragoi et al. concentrated on diclofe-
nac-induced DILI and studied the proteome of monocyte- 
derived hepatocyte-like (MH) cells, then validated the find-
ings in the whole blood to identify potential individual 
susceptibility to diclofenac-induced liver injury [23]. Briefly, 
monocytes were isolated from patients’ blood samples and 
cultivated under serum-free conditions for 10 days, generat-
ing cells with some hepatocyte features, such as cyto-
chrome P450 activities. These cells, MH cells, were 
incubated for 48hours in 96-well plates using 1xCmax and 
10xCmax of the implicated drugs the respective patient had 
consumed. Then, toxicity was measured with a standardized 
algorithm based on the release of lactate dehydrogenase in 
the supernatant and cell lysate [33]. The study revealed that 
the cell adhesion molecule ITGB3 was four-fold up-regulated 
in the MH cells from diclofenac-induced liver injury patients 
and reduced in the whole blood compared to healthy sub-
jects, DILI due to other drugs and patients with other acute 
liver injuries. Also, ITGB3 correlated inversely with liver bio-
chemistry and clinical outcomes, raising the possibility of its 
role as a diagnostic and potentially prognostic biomarker for 
diclofenac-induced liver injury.
Bell et al. investigated serum protein expression patterns in 
patients with idiosyncratic DILI using a mass spectrometry- 
based quantitative proteomic approach [30]. Priority proteins 
were classified according to the quality of peptide identifica-
tion with priority 1 proteins having the greatest likelihood of 
correct identification. The association between phenotype of 
DILI, DILI severity, and its role in causality assessment was 
determined. The diagnostic accuracy of priority 1 proteins 
and clinical characteristics was explored by linear discriminant 
analysis and assessment of AUROC. Apolipoprotein E had the 
greatest power to differentiate DILI patients from healthy 
controls (AUROC = 0.97; 89% correctly classified as DILI). 
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proteins (inter-alpha-trypsin inhibitor (heavy chain H3, iso-
form 1), gelsolin, complement C7, and serum amyloid P) and 
age increased the AUROC to 0.99 with 96% of DILI cases 
correctly detected, performing better than ALT (AUROC = 
0.99; 73% correctly classified DILI). When severity analysis 
was performed, the expression of 9 priority 1 proteins involved 
in acute-phase response, activation of the complement cas-
cade, and peroxisome proliferator-activated receptor (PPAR)-α
was significantly different between groups of different DILI 
severity.
4.1.2.2. Metabolomics. Four included studies explored 
metabolomics as diagnostic tests in DILI. Ma et al. used ultra- 
high performance liquid chromatography-tandem mass spec-
trometry (UHPLC-MS/MS) for metabolomic profiling and 
selected reaction monitoring (SRM) to measure 15 targeted
Table 2. Summary of performance characteristics of diagnostic biomarkers.
Study ID Biomarker/model Reported measure
Traditional 
biomarker Reported measure
Bell et al [30]. Priority 1 proteins AUROC, Percentage correctly classified 
as DILI (accuracy)
AUROC, Percentage correctly 
classified as DILI (accuracy)
Apolipoprotein E 0.97, 89% ALT 0.99, 73%
+ inter-alpha-trypsin inhibitor 
(heavy chain H3, isoform 1)
0.98, 91% AST 0.99, 67%
+ gelsolin 0.99, 92% ALP 0.96, 68%
+ complement C7 0.99, 93% TBL 0.94, 77%
+serum amyloid P 0.99, 95% ALT+AST+ 
ALP+ TBL
0.99, 81%
+ age 0.99, 96%
Ma et al. [32] Bile acids AUROC Traditional 
biomarkers
AUROC
GCA 0.978 ALT 0.97
TCA 0.985 AST 0.97
TUDCA 0.909 GGT 0.97
GCDCA 0.954 ALP 0.85





Soga et al [28]. C-glutamyl dipeptides AUROC (95% CI)
MLR using (ALT, γ-Glu-Citrulline) in the training 
cohort
0.817 (0.639–0.995)
MLR using (ALT, γ-Glu-Citrulline) in the 
validation cohort
0.849 (0.763–0.934)
Zhang et al. 
[25]
Serum metabolites AUROC (95% CI)
PE 22:6 0.939 (0.822 −1.0)
Crotonyl-CoA 0.933 (0.764 −1.0)
Indole-5,6-quinone 0.917 (0.789– 0.989)
2E-tetradecenoyl-CoA 0.911 (0.789 −1.0)
Phenyllactic acid 0.906 (0.767 −0.983)
Phosphoribosyl-ATP 0.900 (0.767 −0.978)
Huang et al. 
[29]
Decision tree classification model AUROC, accuracy





Candidate biomarkers AUROC (95% CI)
miR-122 0.93 (0.88–0.98)
K18 0.80 (0.72–0.87)
Church et al 
[27].
Candidate biomarkers AUROC (95% CI) Traditional 
biomarkers
AUROC (95% CI)
K18 0.947 (0.928–0.966) ALT 0.99 (0.984–0.996)
FABP1 0.916 (0.890–0.941) AST 0.975 (0.963–0.987)
ccK18 0.911 (0.887–0.935) ALP 0.902 (0.873–0.930)











Abbreviation: GCA: glycocholic acid, TCA: taurocholic acid, TUDCA: tauroursodeoxycholic acid, GCDCA: glycochenodeoxycholic acid, TDCA: taurodeoxycholic acid, 
TBL: total bilirubin, DCA: deoxycholic acid, LCA: lithocholic acid, CDCA: chenodeoxycholic acid, total cytokeratin 18 (K18); liver fatty acid-binding protein (L-FABP); 
caspase cleaved cytokeratin 18 (ccK18); glutamate dehydrogenase (GLDH); macrophage colony-stimulating factor receptor (M-CSF-R); microRNA-122 (miR-122); 
alpha-fetoprotein (AFP); glutathione-S-transferase α (GSTα); sorbitol dehydrogenase (SDH); osteopontin (OPN); cadherin 5 (CDH5); (PON1, normalized to 
prothrombin protein); arginase 1 (ARG1); leukocyte cell-derived chemotaxin 2 (LECT2). 
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bile acid metabolites [32]. They identified six bile acid meta-
bolites that significantly differentiated DILI from controls and 
correlated with DILI severity for glycocholic acid (GCA) 
(AUROC= 0.978) and for taurocholic acid (TCA) (AUROC= 
0.985) as per Table 2. Soga and colleagues took a different 
approach by analyzing metabolites from patients with nine 
different types of liver diseases using capillary electrophoresis 
and liquid chromatography-mass spectrometry [28]. They dis-
covered c-glutamyl dipeptides as potential diagnostic biomar-
kers in liver injury. Consequently, they developed a multiple 
logistic regression model that differentiated DILI from other 
liver pathologies by using ALT and γ-Glu-Citrulline (AUROC= 
0.817; 95% CI 0.639–0.995 in a training cohort, and AUROC = 
0.849; 95% CI 0.763–0.934 in a validation cohort).
Following the rising number of DILI cases from 
Polygonum multiflorum Thunb. (PM), Zhang et al. and 
Huang et al. studied the metabolomic profile of PM- 
induced liver injury [25,29]. Zhang et al. aimed to predict 
PM-induced liver injury by studying baseline metabolites of 
female patients who developed liver injury following PM 
exposure [25]. They identified 25 major differential serum 
metabolites in patients susceptible to PM-induced liver 
injury, involving sphingolipid, glycerophospholipid, fatty 
acid, histidine, and aromatic amino acid metabolism. The 
diagnostic accuracy of six metabolites, PE 22:6, indole- 
5,6-quinone, 2E-tetradecenoyl-CoA, crotonoyl-CoA, phenyl-
lactic acid, phosphoribosyl-, ATP, to differentiate between 
groups was significant with AUROC ≥ 0.9 as shown in 
Table 2. On the other hand, Huang et al. examined the 
metabolomic characteristics of patients with PM-induced 
liver injury compared to healthy volunteers and patients 
with auto-immune hepatitis (AIH) and hepatitis-B virus 
infection (HBV) [29]. They reported changes in multiple 
metabolic pathways in PM-induced liver injury group, 
including metabolisms of essential amino acids (tryptophan, 
valine, phenylalanine), glycerophospholipid metabolism, pri-
mary bile acid biosynthesis, and sphingolipid metabolism. 
The authors used the ratios of P-cresol sulfate/phenylalanine 
and inosine/bilirubin in a decision tree analysis to differenti-
ate PM-induced liver injury from AIH and HBV with sensitiv-
ity of 92.3% and specificity of 88.9%.
4.1.2.3. Immune analytes. Steuerwald et al. explored 
immune profiles by measuring cytokines, chemokines, and 
growth factors in serum at DILI onset and 6-month follow-up 
[31]. They found a significant difference in 19 out of 27 ana-
lytes studied with a strong association with jaundice alone 
regardless of ALT or AST levels. Interestingly, there was no 
significant association with DILI severity or drug class. In addi-
tion, when DILI patients were grouped according to their 
immune profiles, most patients were fitted with adaptive or 
innate immune profiles.
4.1.2.4. Candidate biomarkers. Three studies explored the 
diagnostic abilities of candidate biomarkers. Thulin et al. and
Rupprechter et al. focussed on DILI in prospectively treated 
cohorts with TB/HIV [24,26]. Both studies measured miRNA- 
122 (miR-122) and total keratin18 and correlated changes with 
ALT activity. However, Rupprechter et al. assessed serum bio-
markers with only two cases of pre-defined DILI [26], whereas 
Thulin et al. measured plasma biomarkers including caspase- 
cleaved keratin 18 (ccK18), GLDH, and AFP [24]. All biomarkers 
in both studies were correlated with ALT except AFP, with 
miR-122 being the most sensitive biomarker with an 8-fold 
increase in samples with an elevated ALT > ULN [26]. It was 
apparent that K18 showed a less significant correlation with 
ALT with a transient elevation in the first week of injury 
compared to other biomarkers that showed a persistent eleva-
tion for a few weeks following liver injury [24]. Moreover, miR- 
122 showed a superior accuracy of detecting ALT elevation > 
ULN compared to K18 (AUC= 0.93 and 0.80, respectively). The 
specificity of K18, miR-122, and GLDH to the liver compared to 
muscle was demonstrated by their stable levels in a muscle 
injury cohort compared to ALT.
In an international collaborative study, Church et al. found 
that, among 14 biomarkers studied in the largest cohort to 
date, only four biomarkers (K18, ccK18, FABP1, and GLDH) 
showed high accuracy to detect DILI with AUROC > 0.9 [27]. 
GLDH demonstrated the strongest correlation with ALT in 
Church’s cohort (GLDH, r = 0.88; miR-122, r = 0.66).
4.2. Prognostic studies
4.2.1. Study design
Six case-control studies evaluated the prognostic ability of 
novel biomarkers in DILI. One study had patients with acute 
liver injury from other etiologies as a comparator (n = 22) [34], 
another study compared acute DILI patients, acute liver failure 
patients due to several etiologies (idiosyncratic DILI (n = 39), 
auto-immune hepatitis (n = 38), viral hepatitis (n = 28), and 
acetaminophen overdose (n = 13)), and healthy controls 
(n = 63) [35]. In contrast, healthy volunteers were the main 
control arm in the other studies.
Four studies were conducted in the DILIN cohort 
[27,31,35,36]. One study, Peta et al. included patients from 
the SAFE-T-DILI project [34], and the remaining study popula-
tion was recruited from a single study center in China [37]. 
Five out of six studies defined DILI using the thresholds pro-
posed in DILIN prospective study (ALT or AST > 5 times ULN or 
ALP > 2 times ULN in the absence of jaundice or coagulopa-
thy, or total bilirubin ≥2.5 mg/dL or INR > 1.5 and elevations of 
ALT, AST, or ALP) [27,31,35–37]. Peta et al. defined DILI using 
the less stringent SAFE-T criteria (ALT > 3 times ULN or ALP > 2 
times ULN) [34].
Prognostic biomarkers varied across studies as well as end-
points. Three studies developed prognostic models to predict 
death at 6 months of DILI onset [31,36] compared to Church 
et al. who combined death and liver transplantation at 
6 months as their endpoint [27]. Xie et al. evaluated the DILI 
severity [37], whereas Peta et al. focused on the DILI recovery 
at 12 weeks [34].
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4.2.2. Performance characteristics of prognostic 
biomarkers
Peta and colleagues [34] assessed the prognostic value of 
some of the ActiTest components (apolipoprotein-A1 
[ApoA1], haptoglobin [HAPTO], alpha-2 macroglobulin [A2M] 
and GGT) as predictors of recovery outcome at 8 to 12 weeks 
(defined as <2 times ULN for both ALT and TBL). High levels of 
ApoA1 and HAPTO were found as predictive biomarkers of 
recovery (AUROC = 0.663; 95% CI 0.563–0.760, and 
AUROC = 0.619; 95% CI 0.496–0.718, respectively). Indeed, 
a model including all four evaluated ActiTest components 
plus age and sex showed a significant predictive value for 
recovery, with an AUROC of 0.723 (95% CI 0.610–0.806). 
Moreover, they tried to evaluate the risk of liver fibrosis fol-
lowing DILI using FibroTest [38] and transient elastography 
(TE), but the small sample size and short follow-up limited 
their assessment.
One study, Xie et al., aimed to evaluate DILI-related 
changes in metabolic and immune pathways, using gas chro-
matography-mass spectrometry and UHPLC-MS/MS techni-
ques to identify biomarkers of DILI severity [37]. A total of 31 
metabolites with a different expression between severe and 
non-severe DILI patients were identified, jointly with five cyto-
kines (PDGF-bb, IP-10, IL-1Rα, MIP-1b, and TNF-α) whose 
serum levels were significantly lower in severe compared to 
non-severe patients. Indeed, a model developed to differenti-
ate severe from non-severe DILI cases, including both meta-
bolites and immune mediators, yielded an AUROC of 0.983. In 
addition, differences in the serum levels of K18 were also 
studied. Caspase cleaved K18 concentrations (ccK18) were 
higher in severe DILI patients, though the authors did not 
find differences in total K18 concentration or ccK18/total K18 
ratio between severe and non-severe patients.
Steuerwald et al. analyzed 27 serum immune analytes in 
acute DILI cases from the DILIN cohort, including 14 cytokines, 
seven chemokines, and six growth factors, to elucidate the 
profiles associated with worsened prognosis [31]. Lower levels, 
below the median, of the four immune analytes (IL-9, IL-17, 
PDGF-bb, and RANTES) were predictive of 6-month mortality 
with a 92% accuracy (95% CI 86–98). Furthermore, when com-
bining these lower levels of immune analytes and lower levels 
of albumin (below 2.8 g/dL), the model showed an improved 
accuracy to 96% (95% CI 92–100).
In a more recent study, Bonkovsky and colleagues [35] 
aimed to replicate the findings of Steuerwald et al. [31] in 
a different DILIN cohort, and acute liver failure patients 
enrolled in the Acute Liver Failure Study Group. Multi- 
comparison analyses between acute DILI patients, acute 
liver failure patients with different etiologies and healthy 
controls did not reveal unique patterns of expression of 
immune analytes for a specific etiology. Nonetheless, when 
the authors analyzed levels of immune analytes on sera 
samples from the 127 acute DILI patients, the only inde-
pendent and significant predictor of death at 6 months 
was the combination of low levels of serum albumin 
(below 2.8 g/dL) and low levels of RANTES (below the 
median value of 11,349 pg/mL). This model showed
a high specificity (91%; 95% CI 86–96), but low sensitivity 
(39%; 95% CI 30–47). Also, in subjects enrolled in the DILIN 
cohort, Russo et al. studied the miRNA profile predictive 
power in death within 6 months of DILI onset [36]. They 
found in acute DILI cases, compared to control subjects, 
higher levels of eight miRNAs (miR-122, −1246, −4270, 
−4433, −4463, −4484, −4532, and pre-miR-4767) and 
decreased levels of three miRNAs (miR-455-3p, 1281, pre- 
miR-4274). Among these 11 miRNAs, lower values of three 
of them (miR-122, −4463, pre- miR-4270) were associated 
with 6-month mortality. Remarkably, no subjects with 
higher values (above the median) of miR-122 died within 
6 months. Thus, the authors developed a model combining 
lower levels of albumin (below 2.8 g/dL) and miR-122 
(below the median), which showed the highest sensitivity 
(100%) and reasonable specificity (81%) for 6-month 
mortality.
In an international collaborative effort, Church and col-
leagues evaluated the prognostic performance for death/ 
liver transplantation in DILI patients of 5 traditional and 
10 candidate prognostic biomarkers [27]. Among tradi-
tional biomarkers, they found that increased INR, total 
bilirubin, and AST levels were strongly associated with 
death/liver transplantation (AUROCs > 0.7). Among the 
candidate biomarkers, the higher levels of OPN, K18, 
MCSFR, ccK18, FABP1, and AFP showed their value as 
predictors of fatal outcome (Table 3). To improve the 
available prognostic models, a decision tree model was 
built combining the MELD score and two identified candi-
date biomarkers (K18 and MCSFR). This latter model 
yielded the same sensitivity (0.933) as the MELD score 
(using a threshold of 20 to 29 points) but showed an 
improved specificity (0.899).
4.3. Methodological quality of included studies
4.3.1. Diagnostic studies
We appraised the quality of diagnostic studies using QUADAS- 
2 with adjusted signaling questions to tailor the review. We 
assessed the quality of the studies in all four main domains 
when applicable. We included ten diagnostic studies, all of 
which were case control in methodological design. A summary 
of the quality assessment across the included studies is shown 
in Table 4.
The selection of DILI patients or samples was unclear in 
four diagnostic studies [27–30] compared to other diagnostic 
studies in which patients were recruited prospectively [23– 
26,32]. Steuerwald et al. specified that DILIN patients used in 
the study were recruited prospectively over a specific time 
frame, so we considered it as a low risk of bias [31]. 
Applicability was judged to be of low concern in all studies 
except Thulin et al. due to apparent baseline imbalances and 
different treatment regimes [24].
Due to the rarity of DILI and the nature of the diagnosis, 
which is based on biochemical alteration and causality 
assessment, there is potentially a risk of bias being aware 
of the reference standard prior to conducting new index
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diagnostic tests. Therefore, having a pre-specified thresh-
old for the index test studied before analysis is important 
to avoid potential overfitting diagnostic accuracy that can 
limit the external validity of the results. The threshold 
values were pre-specified in Rupprechter et al. [26], 
Church et al. [27], and Steuerwald et al. [31], so we classi-
fied them as low risk of bias compared to other studies.
In the reference standard domain of risk of bias assess-
ment, we considered undertaking causality assessment in 
addition to elevation of liver enzymes as a quality measure 
for identifying DILI cases. Five included studies followed 
the RUCAM causality assessment score as the reference 
standard to establish DILI cases and were classified as 
low risk of bias [23,27,30–32]. In contrast, three prospective 
studies defined cases based on ALT elevation alone follow-
ing drug exposure and were therefore judged as high risk 
of bias [24–26]. Two studies, Soga et al. and Huang et al., 
did not specify a reference standard for defining DILI cases 
[28,29].
We have considered specifying the interval between DILI 
occurrence and blood sampling as a quality measure, which 
was not clearly defined in four studies [23,28,29,32]. It was 
unclear if all patients in Steuerwald et al. had causality 
assessment and adjudication [31]. In Bell et al. study, 
a proportion of patients did not receive the reference stan-
dard and was therefore classified as high risk of bias [30].
4.3.2. Prognostic studies
We used the quality of prognostic study tool (QUIPS) to 
appraise the quality of six included studies that investigated 
prognostic biomarkers or models, as shown in Table 5. The 
population in Peta et al. included only mild cases of DILI with 
ALT ranging from 244 to 414 U/L and was therefore judged as 
a moderate risk of bias [34]. The remaining studies included 
patients with all grades of DILI severities and were at low risk 
of bias. Russo et al. and Steuerwald et al. were deemed as 
moderate risk of attrition bias as they included the same DILIN 
population with over half of the patients lost from follow-up at 
6 months [31,36]. However, Bonkovsky et al. was considered as 
low risk of attrition bias as no subjects from the chosen DILIN 
cohort lost follow-up [35]. We judged all studies as moderate 
risk of bias in the prognostic factor measurement domain as 
prognostic models reported have not been validated and the 
cut-off values used were chosen following exploratory analysis 
of biomarkers. We judged all studies as low risk of bias in the 
outcome measurement domain except Peta et al. [34]. The 
authors used DILI recovery at 12 weeks as an endpoint 
(defined as ALT < 2 ULN and TBL < 2 ULN), which is not a well- 
validated clinical endpoint in DILI.
Four studies included samples from the DILIN cohort and 
reported mortality at 6 months [27,31,35,36]. However, confoun-
ders for death were not clearly specified with only half of deaths 
being due to liver disease [36]. Therefore, we classified the risk of 
bias as moderate in the above studies for the study confounding 
domain.
All included studies presented data sufficiently and built 
prognostic models based on a conceptual framework with low 
concern regarding selective reporting of results, except for 
Bonkovsky et al., who did not report the AUROC values though 
it was planned in the statistical analysis [35].
5. Discussion
In this first systematic review focused on the application of 
biomarkers for the diagnosis of idiosyncratic DILI and prog-
nostic evaluation of the acute DILI event, we found only 14 
studies overall that met pre-defined criteria for inclusion.
Table 4. Risk of bias summary for diagnostic studies: review authors’ judgments 










Bell 2012 [30] Unclear High Low High
Dragoi 2018 [23] Low High Low Unclear
Ma 2019 [32] Low High Low Unclear
Soga 2011 [28] Unclear High Unclear Unclear
Zhang 2020 [25] Low High High Low
Huang 2020 [29] Unclear High Unclear Unclear
Thulin 2014 [24] Low High High Low
Rupprechter 2020 
[26]
Low Low High Low
Church 2019 [27] Unclear Low Low Low
Steuerwald 2013 
[31]
Low Low Low Unclear












Statistical analysis and 
reporting
Church 2019 [27] Low Low Moderate Low Moderate Low
Russo 2017 [36] Low Moderate Moderate Low Moderate Low
Peta 2017 [34] Moderate Low Moderate Moderate Low Low
Xie 2019 [37] Low Low Moderate Low Low Low
Steuerwald 2013 
[31]
Low Moderate Moderate Low Moderate Low
Bonkovsky 2019 
[35]
Moderate Low Moderate Low Moderate Moderate
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Study designs included both system biology approach and 
candidate biomarker studies to identify putative biomarkers. 
However, assessments of the role of biomarkers in the diag-
nosis of DILI were limited by the fact that only three studies 
included individuals with other liver injuries unrelated to drug 
exposure as a comparator [23,28,29]; hence, the potential of 
a biomarker to distinguish DILI from other alternative etiology 
of acute liver injury was not sufficiently evaluated. Moreover, 
studies investigating DILI biomarkers in patients with under-
lying liver diseases such as nonalcoholic fatty liver disease and 
chronic viral hepatitis are lacking, which highlights another 
important gap in the field.
One prospective DILI cohort was used as a discovery set for 
four different studies, each identifying a different combination 
of biomarkers associated with a particular phenotype or prog-
nosis of DILI [27,31,35,36]. However, data from individual cases 
were not available for further modeling or meta-analysis. In 
the largest longitudinal cohort involving 141 DILI patients, of 
which 15 died or received transplantation, a combination of 
MELD score, serum K18 and MCSFR was able to identify 14 out 
of 15 with adverse outcomes [27]. The latter algorithm, as well 
as significant findings from other cohort studies, 
requires validation in a further independent cohort.
The few biomarkers that have been assessed in more than 
one study include K18, GLDH, AFP, and miR-122 
[24,26,27,36,37]. Both K18 and ccK18 have been elevated dur-
ing drug therapy of combination therapy for tuberculosis and 
HIV [24], and the relationship between DILI and the ratio 
between the two was inconsistent in different studies [27,37].
The diagnostic value of the AFP was evaluated in two studies 
[24,27]. In the TB/HIV study, AFP was the only biomarker that did 
not correlate with ALT, which might be explained by its role as 
a cell regeneration marker rather than a liver injury. Its prognos-
tic role in intrinsic DILI has been well described, and an increase 
in AFP level was shown to predict favorable outcome in para-
cetamol-induced liver injury [39]. In contrast, in an idiosyncratic 
DILI cohort, raised AFP levels significantly predicted death or 
liver transplantation at 6 months [27].
miR-122 was the most sensitive biomarker to elevate from 
baseline following hepatotoxic drugs and reached 
a sensitivity of 100% for predicting death in 6 months 
when combined with albumin [24,26,36]. Furthermore, 
a recent study explored its potential practical use as a point- 
of-care biomarker by measuring its level in capillary blood 
[40]. Despite its value, the significant interindividual variabil-
ity of miR-122 shown by Church et al. and Rupprechter et al. 
limits its use as a liver-specific biomarker [26,27]. Therefore, 
PSTC has recently prioritized GLDH over mir-122 to pursue 
biomarker qualification [27]. The time between DILI detec-
tion and blood sampling might contribute to the variability 
of biomarkers and lacked standardization across studies. 
Blood sampling in the DILIN cohort was performed within 
2 weeks of the liver injury compared to 4 weeks in the SAFE- 
T cohorts. Nonetheless, Church et al. did not find a significant 
correlation between the levels of biomarkers and the time 
between symptom onset and blood sampling [27]. It also
generated a controversy whether degradation with time in 
the samples used by Church et al. played a part in this 
variability [27]. However, there was no correlation between 
sample age and miR-122 variation in the SAFE-T healthy 
volunteers [41,42].
Despite choosing a low threshold for case finding of DILI, 
targeted bile acid metabolites were strongly predictive of early 
diagnosis of DILI and significantly increased in proportion to 
the severity of the liver injury. However, these findings have 
not been validated in a second cohort, a limitation with most of 
the positive findings described. In contrast, the proteomics 
approach identified apolipoprotein E as a potential biomarker 
in DILI which was not differentially expressed in a nonalcoholic 
fatty liver disease (NAFLD) cohort [30]. Moreover, when Soga 
and colleagues studied metabolomic profiles in different liver 
diseases, c-glutamyl dipeptides were increased in all liver inju-
ries compared to healthy controls [28]. This elevation may 
represent reduced hepatocellular glutathione (GSH) produc-
tion; however, different types of c-glutamyl dipeptide showed 
variable elevation across liver pathologies for an unclear rea-
son. In DILI patients, γ-Glu-Citrulline was significantly elevated 
and showed high diagnostic accuracy when integrated with 
ALT in a statistical model.
Following the rising number of DILI cases globally from the 
traditional Chinese medicine Polygonum multiflorum Thunb. 
[43,44], two Chinese studies explored metabolic profiles of 
PM-DILI at different time points [25,29]. One study investi-
gated potential metabolic risk factors of PM-induced liver 
injury and found differences in baseline metabolites linked 
to multiple metabolic pathways suggesting low-grade inflam-
mation and immune dysfunction in individuals susceptible to 
PM-induced liver injury [25]. This was consistent with previous 
data, which highlighted that patients with auto-immune dis-
eases were more likely to develop PM-induced liver injury [45]. 
On the other hand, the other study identified metabolic sig-
nals in PM-induced liver injury cases, mainly in amino acids 
and sphingolipid metabolisms, compared to healthy and liver 
injuries secondary to auto-immune hepatitis or HBV infec-
tion [29].
Primary bile acid biosynthesis and alpha-linolenic acid 
metabolism pathways have been linked to the severity of 
DILI. The level of metabolites negatively correlated with pro- 
inflammatory (PDGF-bb, TNF-α, IP-10, and MIP-1b) and anti- 
inflammatory cytokines (IL-1Rα) [37]. However, the significant 
reduction in most of the cytokines’ levels in severe DILI 
patients may represent a state of immune dysfunction or 
immune paresis that has been observed in patients with 
acute liver failure [46]. In the DILIN cohort, five cytokines (IL- 
12, IL-17, PDGF-bb, RANTES, and TNF-α) were lower in patients 
with acute liver failure; and in a Chinese cohort, levels of 
PDGF-bb and TNF-α were lower in the severe DILI group 
[31,37]. Therefore, cytokines may have a future role in predict-
ing patients with a high risk of dying following DILI.
Systematic identification of DILI remains difficult and labor 
intensive even in hospitalized patients [47]. Despite the devel-
opment of several diagnostic DILI biomarkers, clinicians still
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face a challenge trying to identify the culprit drug in patients 
who take multiple medications. In vitro methods, using mono-
cyte-derived hepatocyte-like (MH) cells from peripheral blood 
of DILI patients, have been developed to identify drugs that 
caused DILI with high specificity [33].
Besides its novelty and relevance in the field, the strengths of 
this review include the adoption of high methodological stan-
dards by performing a comprehensive literature search, detailed 
scrutiny of included studies, and rigorous independent risk of 
bias assessment. The review included a small number of studies, 
the majority of which in turn included a small number of parti-
cipants. In addition, data from heterogeneous populations and 
outcomes, were unsuitable for pooling in quantitative analysis. 
This systematic review demonstrated the potential for a system 
biology approach in the derivation cohort with serum metabo-
lome and targeted bile acid profiling, revealing the role of bile 
acid metabolism in DILI pathogenesis [32].
6. Conclusion
Our systematic review emphasizes that there is a clear case of 
need for research in this area. The low prevalence of DILI may 
explain the challenges of conducting such studies; therefore, 
larger prospective studies with collaborative efforts are 
required to qualify candidate biomarkers and suggest that 
a coordinated iterative process is needed.
7. Expert opinion
There is an important case of need both during drug- 
development and clinical practice for new tests that distin-
guish DILI from alternative etiology for acute liver injury and 
chronic liver diseases. Biomarkers that distinguish self- 
resolving elevation of liver enzymes (referred to as adapta-
tion), and therefore recovery, from progression and therefore 
serious liver injury in DILI will transform monitoring in clinical 
trials and strengthen regulatory approval of novel molecular 
entities. These safety biomarkers are crucial to reduce the late 
attrition of drugs during their pre-clinical development and 
post-marketing withdrawals as well as for effective monitoring 
of drug therapy in clinical practice.
Interestingly, innovative research methodologies such as gen-
ome-wide association studies (GWAS) have been adopted in DILI 
research soon after their introduction. This delivered a major 
breakthrough [48] and triggered the formation of a large global 
research collaboration leading to identification of genetic mar-
kers associated with DILI secondary to over 20 of currently used 
medications [49,50]. Surprisingly, other system biology 
approaches and technologies are yet to yield similar success. 
One of the key reasons for lack of progress is that the study 
should be designed to identify patients with acute liver injury 
early in the course of the event, even before diagnosis is con-
firmed (for which the study should be seamlessly integrated into 
clinical pathways and enroll sufficient number of cases of uncom-
mon, yet a serious adverse event to match the context of use of
the candidate biomarkers. Only multicenter collaboration with 
harmonized protocols can deliver such a program effectively.
It was striking to note that the most relevant full texts 
identified in the search were review articles rather than 
primary studies. Hence, time is ripe for a step change in 
the field and to focus future academic efforts on primary 
research. First of all, candidate biomarkers identified 
through the most robust studies highlighted in our sys-
tematic review should be prioritized for validation. 
Currently, the combination of K18 and MCSFR, when used 
in conjunction with MELD score, is the only panel that 
appears to add value in prognostication of DILI event. As 
technologies mature investigations exploring the utility of 
new biomarkers such as microRNAs and extracellular vesi-
cles will follow. It is important to recognize that several 
lines of evidence highlight the role of adaptive immune 
response as the common distal event in the development 
of DILI. Moreover, future drug pipeline is enriched by small 
molecules and biologics targeting the immune system. 
Therefore, characterization of immune mechanisms under-
pinning DILI may reveal biomarkers that typify the event. 
Unique features of circulating and infiltrating cell types 
may be carrying the hallmarks of DILI.
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